18. November 2009 04:01
NicOx S.A. today announced that it has received a filing communication from the U.S. Food and Drug Administration (FDA) stating that the New Drug Application (NDA) for naproxcinod is accepted for filing. NicOx submitted the NDA on September 24th, seeking approval for the relief of the signs and symptoms of osteoarthritis.
[More]
16. November 2009 05:36
On Sunday, November 15, 2009, Florida Atlantic University (FAU) researcher Charles H. Hennekens, M.D., the first Sir Richard Doll Research Professor in the Charles E. Schmidt College of Biomedical Science will present at the American Heart Association's Annual Scientific Sessions meeting in Orlando, FL, the first data in humans to show that all doses of aspirin used in clinical practice increase nitric oxide.
[More]
13. November 2009 01:45
NicOx S.A. today announced that a phase 1b, first-in-man study for NCX 6560, versus placebo and Lipitor® (atorvastatin), has met its primary and secondary objectives. The top-line results demonstrated very good safety and tolerability for all the tested doses of NCX 6560, as well as the expected cholesterol lowering profile.
[More]
16a7012b-d78f-446e-9b5b-14867f97637f|0|.0
Posted in: Drug Trial News | Medical Condition News
Tags: Anti-Inflammatory, Atherosclerosis, Atorvastatin, Cholesterol, Coronary Heart Disease, Lipoprotein, New Drug Application, Nitric Oxide, Osteoarthritis, Stroke, Thrombosis
6. November 2009 00:39
Infants who are exposed to higher levels of air pollution are at increased risk for bronchiolitis, according to a new study.
[More]
5. November 2009 01:09
New research shows that during natural menstrual cycles, women with asthma who were not taking oral contraceptives (OC) had lower exhaled nitric oxide levels (eNO), a marker of airway inflammation associated with asthma, than women who were taking OC.
[More]
4. November 2009 04:48
A new study compares neighborhoods' walkability (degree of ease for walking) with local levels of air pollution and finds that some neighborhoods might be good for walking, but have poor air quality. Researchers involved in the study include University of Minnesota faculty member Julian Marshall and University of British Columbia faculty Michael Brauer and Lawrence Frank.
[More]
4. November 2009 04:32
Inhaled nitric oxide (iNO), a therapy used in the treatment of premature newborns with respiratory failure that had shown promising results in short-term studies, does not significantly improve long-term outcomes, according to a national study led by critical care researchers at the University of Pittsburgh School of Medicine and Children's Hospital of Pittsburgh of UPMC.
[More]
4. November 2009 03:34
Aerocrine AB today announced that Aerocrine and Panasonic Shikoku Electronics, CO., LTD (PSEC) have entered into a long-term agreement to develop, manufacture and market new generation products for airway inflammation monitoring using exhaled nitric oxide.
[More]
3. November 2009 23:49
Aerovance Inc. today announced it has completed patient enrollment in a Phase 2b clinical trial of the inhaled dry powder formulation of Aerovant for the treatment of uncontrolled asthma. Top-line results are expected by the second quarter of 2010.
[More]
28. October 2009 05:56
Diabetic patients diagnosed with peripheral neuropathy had lower medical costs and reduced use of anticonvulsant medications when treated with a folate-enriched prescription medical food, according to data presented today at the International Society for Pharmacoeconomics and Outcomes Research 12th Annual European Congress.
[More]
28. October 2009 05:50
Research & Diagnostic Antibodies LLC (R&D Antibodies) announced today that it has received a notification stating that the European Patent Office intends to grant a patent for its monoclonal antibody-based immunoassays and apparatuses for measuring inducible nitric oxide synthase (iNOS) as a plasma biomarker for the early detection of the sepsis pathology.
[More]
27. October 2009 06:06
Diabetic patients diagnosed with peripheral neuropathy had lower medical costs and reduced use of anticonvulsant medications when treated with a folate-enriched prescription medical food, according to data presented today at the International Society for Pharmacoeconomics and Outcomes Research 12th Annual European Congress.
[More]
22. October 2009 01:58
NicOx S.A. today reported financial results for the nine months ended September 30, 2009.
[More]
20. October 2009 02:24
NicOx S.A. announced the presentation of detailed 26-week efficacy, safety and tolerability data from the second pivotal phase 3 study for naproxcinod (the 302 study) yesterday, at the American College of Rheumatology (ACR) and Association of Rheumatology Health Professionals (ARHP) Annual Scientific Meeting in Philadelphia, Pennsylvania.
[More]
14. October 2009 02:34
Researchers at Texas State University-San Marcos have completed initial testing of a cancer chemotherapeutic and anti-retroviral compound with promising results.
[More] 
Subscribe